logo
Apple doesn't have to make products in the US: Former Commerce Secretary Wilbur Ross

Apple doesn't have to make products in the US: Former Commerce Secretary Wilbur Ross

Yahoo14-05-2025
Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, Amazon Music, YouTube or wherever you find your favorite podcasts.
When push comes to shove, Apple (AAPL) will manufacture where it's best for its shareholders and bottom line — even if it draws the ire of tariff-wielding President Trump.
"Apple are very clever strategists. And remember, their purpose is not to boost the economy. Their purpose is to maximize profit. So they will clearly use whatever strategy accomplishes that goal," billionaire businessman and longtime Trump confidant Wilbur Ross told me on Yahoo Finance's Opening Bid podcast (see video above or listen below).
Ross served as the 39th US Commerce secretary from 2017 to 2021 and is the author of "Risks and Returns: Creating Success in Business and Life." During his tenure, Ross helped implement Trump's first tariffs on China.
This embedded content is not available in your region.
"I think [Apple CEO Tim Cook] will make products where it makes the most sense. You'll notice what he started with is moving assembly out of China to India," Ross said. He added the move doesn't help the US, but could help in the future if the local industry grows and starts sourcing American semiconductors instead of rival ones.
Apple — long reliant on China factories to build its lucrative iPhone — has been caught in the crosshairs of the trade war that looks to finally be ratcheting down a notch.
After a weekend of high-level meetings in Switzerland, the US will reduce "reciprocal" tariffs on goods from China to 10% from 125%. A separate 20% tariff imposed by Trump over what he says is China's role in the fentanyl trade will remain intact.
China will cut its retaliatory tariffs on US goods to 10% from 125%.
Read more: What Trump's tariffs mean for the economy and your wallet
In April, the administration had issued a rule that spared smartphones, computers, semiconductors, and other electronics from reciprocal tariffs, though the 20% fentanyl tariffs still applied to Chinese goods.
The tariff reprieve has sparked a market rally, with the S&P 500 (^GSPC) up 4% since Monday and now trading around flat for the year.
Apple has used the trade policy uncertainty to diversify its supply chain and toss a bone to Trump. It pledged in February to invest $500 billion in the US, mostly tied to a new manufacturing facility in Houston to pump out servers that support Apple Intelligence.
Absent from the commitment was anything related to making consumer hardware in the US. Cook said in a 2015 interview that a skills gap in the US makes it difficult to produce Apple's products stateside.
"So I think you will see iPhones being made in India, less in China, and you'll see iPhones being made in the US and strike the balance on it. So I think this is one where you will see us get very close to key allies. I think the most important strategic partnership we have in the world is with India, and I think you'll see them lay the groundwork for a good working relationship in resolving the tariff issues effectively," former Cisco (CSCO) CEO John Chambers told me on Yahoo Finance's Catalysts.
Three times each week, Yahoo Finance Executive Editor Brian Sozzi fields insight-filled conversations and chats with the biggest names in business and markets on Opening Bid. You can find more episodes on our video hub or watch on your preferred streaming service.
Brian Sozzi is Yahoo Finance's Executive Editor. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email brian.sozzi@yahoofinance.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump's BLS Pick Calls For Suspension Of Monthly Jobs Report: Data 'Needs To Be Fixed Immediately'
Trump's BLS Pick Calls For Suspension Of Monthly Jobs Report: Data 'Needs To Be Fixed Immediately'

Yahoo

time27 minutes ago

  • Yahoo

Trump's BLS Pick Calls For Suspension Of Monthly Jobs Report: Data 'Needs To Be Fixed Immediately'

E.J. Antoni, the economist tapped by President Donald Trump to lead the Bureau of Labor Statistics and an architect of the Heritage Foundation's Project 2025, suggested the agency should suspend monthly jobs reports in a Tuesday television appearance. Antoni appeared on Fox Business Tuesday morning to discuss Trump's lack of confidence in the Bureau's monthly job data. 'How on earth are businesses supposed to plan – or how is the Fed supposed to conduct monetary policy – when they don't know how many jobs are being added or lost in our economy? It's a serious problem that needs to be fixed immediately,' Antoni told FOX Business. Suspending Job Reports: A Risky Proposition Trump nominated Antoni to the position after his unprecedented firing of former BLS Chief, Erika McEntarfer, on Aug. 1. The Bureau's July jobs report showed nonfarm payrolls rising by 73,000, far below economists' estimates of 110,000. The report also included a revision of May and June's tallies, down by over 100,000 each. Similar revisions were observed during the Biden Administration. 'Until it is corrected, the BLS should suspend issuing the monthly job reports but keep publishing the more accurate, though less timely, quarterly data,' Antoni added. 'Major decision-makers from Wall Street to D.C. rely on these numbers, and a lack of confidence in the data has far-reaching consequences.' Can Data Integrity Survive Political Pressure? Trump called the jobs report 'rigged' and 'fake' following his firing of McEntarfer. Top economists dismissed Trump and Antoni's insinuations and reiterated that attempts to erode the independence of reporting agencies could sow distrust in markets. '[Suspending monthly jobs reports] would [be] a serious mistake in my estimation. It would only fuel critiques of a politicization of job market data and likely result in volatility across asset classes,' RSM US chief economist Joe Brusuelas told Axios. Withholding or fabricating economic data is a common practice observed in many authoritarian regimes, such as the Soviet Union during the 1980s. The Dangers Of Distrust In Economic Data University of Michigan professor Justin Wolfers described Antoni as unqualified for the position in a post on X. 'Antoni finished grad school 5 years ago at Northern Illinois with no obvious distinction, his dissertation is meh, and involved no research on labor markets or data collection, he has never published a paper, and his life's work has earned 1 citation,' Wolfers said. 'This record would be insufficient to earn a job as a junior staffer at BLS.' Also Read:Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Trump's BLS Pick Calls For Suspension Of Monthly Jobs Report: Data 'Needs To Be Fixed Immediately' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

Yahoo

time27 minutes ago

  • Yahoo

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. Brinsupri is the first and only FDA-approved treatment for NCFB, a chronic lung condition characterized by permanently widened and damaged airways (bronchi), leading to persistent mucus production, recurrent infections, and difficulty breathing. There are approximately 500,000 people in the U.S. diagnosed with NCFB. The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW ASPEN, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also met several exacerbation-related secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining exacerbation-free over the treatment period. Patients who received Brinsupri 25 mg experienced a statistically significantly less decline in lung function, as measured by forced expiratory volume in one second (FEV₁) after using a bronchodilator, at week 52. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions in WILLOW. In parallel, applications for brensocatib with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory. Price Action: INSM stock is up 6.20% at $119.89 at the last check on Tuesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? INSMED (INSM): Free Stock Analysis Report This article FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

What to Make of Trump's DC Takeover - Amanpour - Podcast on CNN Podcasts
What to Make of Trump's DC Takeover - Amanpour - Podcast on CNN Podcasts

CNN

time27 minutes ago

  • CNN

What to Make of Trump's DC Takeover - Amanpour - Podcast on CNN Podcasts

What to Make of Trump's DC Takeover Amanpour 55 mins The streets of Washington, DC will soon be patrolled by 800 National Guard troops, the city's police will be under federal control for the first time in their history, and homeless people will be forced to leave. According to President Trump, it's all necessary to tackle a purported wave of lawlessness. And while crime is certainly a problem in the capital, Trump's description of a public safety emergency told a slightly different story than the statistics. There's actually been a decrease in crime, with violent crime at a 30-year low. With Trump hinting that Washington is just the first city to face these measures, what does this say about his exertion of executive power? Andrew McCabe was the acting FBI Director in the first Trump administration, he joins the program to discuss. Also on today's show: Victoria Fontan, Rector of the American University of Malta & Mumtaz Islamzay, Afghan Student; David A. Graham, Staff writer, The Atlantic

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store